President and CEO
Randy Lashinski joined Millipede as President and CEO in 2013 bringing to the organization a wealth of experience in early stage company executive leadership and technology innovation in the structural heart space. Prior to Millipede, Randy was the Founder, President and CEO of Claret Medical, a percutaneous, dual-filter company for TAVI procedures. Randy led the early technology invention and established and ran the clinical trial leading to CE Mark and commercialization in Europe and early IDE discussions with the FDA. In addition to Claret, Randy co-founded and was President/CEO and later Chief Technology Officer of Direct Flow Medical, a percutaneous aortic valve company. Prior to Direct Flow, Randy served as Founding Engineer and VP of Research and Development at MitraLife, later sold to ev3, where he developed a device for the treatment of mitral regurgitation. Randy’s early cardiovascular experience included various engineering roles at Arterial Vascular Engineering (AVE) / Medtronic Vascular and Target Therapeutics. Randy received his education in Mechanical Engineering from the University of Minnesota.
Chief Financial Officer
Jay Shukert joined Millipede, Inc. in February 2016 as the Chief Financial Officer. Jay fulfills this role as a consultant and brings more than 25 years of chief financial officer experience in early stage medical device and biotechnology companies. His clients have included Millennium Pharmaceuticals, Prograft Medical, Coalescent Surgical, Spinal Kinetics, Sutro Biopharma, Delinia and PMV Pharmaceuticals. Previous to his work as a consulting CFO, Jay was Vice President, Finance at CV Therapeutics and Controller at Neurex Corporation. Jay has also held financial positions at Genentech and was a manager in the consulting practice at Arthur Andersen & Co. Jay received an MBA from the University of California, Berkeley and a BS from the University of Pennsylvania.
Chief Operating Officer
Richard Glenn joined Millipede, Inc. in 2013, first as a consultant, then Vice President of Research and Development and in 2015 was appointed to the position of COO. Rich brings to the organization a rich history of innovation in early stage companies and technologies. Prior to Millipede, Rich was the Manager of Systems Research and Development at NeuroTronik, Inc., a company focused on treating acute heart failure with an electrophysiology catheter. Here he was instrumental in the development of the catheter platform and initial funding milestones. In addition to NeuroTronik, Rich spent 12 years in engineering and management roles with SyneCor, LLC, a medical device incubator which developed technologies and key discoveries in the cardiovascular, electrophysiology, and gastroenterology spaces resulting in the spin-out of five companies, including selling IP to Boston Scientific and an acquisition by Abbott. Rich spent his early years in engineering roles at IsoStent, Ventritex and Advanced Cardiovascular Systems. Rich received two Bachelor of Science degrees in Industrial Technology and Mechanical Engineering from San Jose State University.
Michael J. Lee
Vice President, Research and Development
Mike Lee joined Millipede, Inc. in 2016 as the Vice President of Research and Development. He brings to Millipede more than 20 years of medical device business and engineering experience. Prior to joining Millipede, Mike founded and was President of Refine LLC, a medical device company developing cosmetic and reconstructive products. In addition to Refine, Mike was Vice President of R&D for Alure Medical, an innovative suspension system acquired by Refine. Mike was involved with Claret Medical where he was a co-founder, consultant and served on the Board of Directors. Prior to Claret, he co-founded Conquest Medical, a percutaneous biopsy company and was Vice President of Engineering for Medlogics, a drug eluting coatings and stent company. Mike was the Director of R&D for BioHeart’s myocardial regeneration injection systems. Mike’s other experience includes Arterial Vascular Engineering, Cardeon and Cardiac Pathways. Mike has a Bachelor of Science in Mechanical Engineering from California Polytechnic State University.
Vice President, Clinical, Regulatory and Quality
Brian Sheahan joined Millipede, Inc. in September 2016, serving as the Vice President of Regulatory, Quality and Clinical Affairs. He is an accomplished clinical and commercial leader with extensive clinical, regulatory and quality expertise bringing new technologies to market. Previously, Brian has served in similar roles with increasing responsibilities at Hansen Medical (sold to Auris Robotics), Direct Flow Medical (EU clinical and commercial launch, pilot study in US), Trivascular (sold to Boston Scientific), Mitralife (sold to ev3), Arterial Vascular Engineering (sold to Medtronic, Vascular Division), PS Medical (sold to Medtronic, Neurosurgical Division), Terumo Medical (initial US R&D and manufacturing site). Brian holds a B.S. degree in Biochemistry from Saint Joseph’s University in Philadelphia, PA.
J. Casey McGlynn
J. Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich & Rosati in 1990. It is a nationally recognized practice representing startups and emerging growth companies in the life sciences field--Medical Devices, Digital Health, Diagnostics and Biotechnology. Casey has formed, sold and taken public many of the most important medical device companies formed during the last 30 years. He has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. Additionally, Casey has close working relationships with an unparalleled list of entrepreneurs, physicians, investors, engineers and senior executives in the life sciences field.